References
- Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11(5):373-84; PMID:20404851; http://dx.doi.org/10.1038/ni.1863
- Ghosh TK, Mickelson DJ, Fink J, Solberg JC, IngleWeld JR, Hook D, Gupta SK, Gibson S, Alkan SS. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cell Immunol 2006; 243(1):48-57; PMID:17250816; http://dx.doi.org/10.1016/j.cellimm.2006.12.002
- Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174:1259-68; PMID:15661881; http://dx.doi.org/10.4049/jimmunol.174.3.1259
- Lu H, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, Inokuma M, Suni M, Maino VC, Henderson KE, Howbert JJ et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 2012; 18:499-509; PMID:22128302; http://dx.doi.org/10.1158/1078-0432.CCR-11-1625
- Harris J, Sengar D, Stewart T, Hyslop D. The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer 1976; 37(2 Suppl):1058-69; PMID:766953; http://dx.doi.org/10.1002/1097-0142(197602)37:2+%3c1058::AID-CNCR2820370813%3e3.0.CO;2-O
- Nakamura I, Shibata M, Gonda K, Yazawa T, Shimura T, Anazawa T, Suzuki S, Sakurai K, Koyama Y, Ohto H et al. Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system. Oncology letters 2013; 5(5):1682-6; PMID:23761834
- Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 2004; 165(6):1853-63; PMID:15579430; http://dx.doi.org/10.1016/S0002-9440(10)63238-5
- Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F, Coukos G. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20(6):607-15; PMID:24793239; http://dx.doi.org/10.1038/nm.3541
- Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8(8):793-800; PMID:12091876
- Dietsch GN, Randall TD, Gottardo R, Northfelt DW, Ramanathan RK, Cohen PA, Manjarrez KL, Newkirk M, Bryan JK, Hershberg RM. Late Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX 2337). Clin Cancer Res 2015; 21(24):5445-52; PMID: 26152744; http:/dx.doi.org/10.1158/1078-0432.CCR-15-0578.